Drug Profile

Ralaniten acetate - ESSA Pharma

Alternative Names: EPI 506

Latest Information Update: 09 Oct 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator ESSA Pharma
Class Antineoplastics; Small molecules
Mechanism of Action Androgen receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Prostate cancer

Most Recent Events

09 Oct 2025 ESSA Pharma has been acquired by XenoTherapeutics
01 Dec 2017 ESSA Pharmaceuticals terminates a phase I/II trial in Prostate cancer (Hormone refractory, Second-line therapy or greater) in United Kingdom, USA, Canada due to excessive high pill burden at the end of phase I (PO) (NCT02606123)
11 Sep 2017 Discontinued - Phase-I/II for Prostate cancer (Hormone refractory, Second-line therapy or greater) in Canada and USA (PO)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com